ViiV Healthcare’s Dovato as effective as Biktarvy in Phase IV HIV trial
While being non-inferior to Biktarvy in viral suppression, Dovato patients also benefitted from lower weight gain.
23 July 2024
23 July 2024
While being non-inferior to Biktarvy in viral suppression, Dovato patients also benefitted from lower weight gain.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.